{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:49:41Z","timestamp":1777938581235,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"1-2","license":[{"start":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:00:00Z","timestamp":1419292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tissue Engineering Part A"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:p>\n                    Following the coordinated efforts of five established scientific organizations, this report describes activity in Europe for the year 2012 in the area of\n                    <jats:italic toggle=\"yes\">cellular and engineered tissue therapies<\/jats:italic>\n                    , excluding hematopoietic stem cell (HSC) treatments for the reconstitution of hematopoiesis. Three hundred thirteen teams from 33 countries responded to the cellular and engineered tissue therapy survey: 138 teams from 27 countries provided data on 2157 patients, while a further 175 teams reported no activity. Indications were musculoskeletal\/rheumatological disorders (36%; 80% autologous), cardiovascular disorders (25%; 95% autologous), hematology\/oncology, predominantly prevention or treatment of graft versus host disease and HSC graft enhancement (19%; 1% autologous), neurological disorders (3%; 99% autologous), gastrointestinal disorders (1%; 71% autologous), and other indications (16%; 79% autologous). Autologous cells were predominantly used for musculoskeletal\/rheumatological (42%) and cardiovascular (34%) disorders, whereas allogeneic cells were mainly used for hematology\/oncology (60%). The reported cell types were mesenchymal stem\/stromal cells (49%), HSC (28%), chondrocytes (11%), dermal fibroblasts (4%), keratinocytes (1%), and others (7%). In 51% of the grafts, cells were delivered after\n                    <jats:italic toggle=\"yes\">ex vivo<\/jats:italic>\n                    expansion, whereas cells were transduced or sorted in 10% and 16%, respectively, of the reported cases. Cells were delivered intra-organ (35%), intravenously (31%), on a membrane or gel (15%), or using 3D scaffolds (19%). The data are compared with those collected since 2008 to identify trends in the field and discussed in the light of recent publications and ongoing clinical studies.\n                  <\/jats:p>","DOI":"10.1089\/ten.tea.2014.0515","type":"journal-article","created":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T01:43:33Z","timestamp":1416966213000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["The Survey on Cellular and Engineered Tissue Therapies in Europe in 2012"],"prefix":"10.1177","volume":"21","author":[{"given":"Ivan","family":"Martin","sequence":"first","affiliation":[{"name":"University of Basel","place":["Switzerland"]},{"name":"University of Basel","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Ireland","sequence":"additional","affiliation":[{"name":"University of Basel","place":["Switzerland"]},{"name":"University of Basel","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Baldomero","sequence":"additional","affiliation":[{"name":"University Hospital Basel","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[{"name":"University Hospital Basel","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,12,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60533-X"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10561-013-9397-6"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tea.2010.0056"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tea.2011.0131"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tea.2012.0169"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tea.2013.0372"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/427863"},{"key":"e_1_3_3_9_2","unstructured":"Osiris Press Release via Business Wire. Osiris Therapeutics announces preliminary results for Prochymal\u00ae phase III GvHD trials. 8 September 2014."},{"key":"e_1_3_3_10_2","unstructured":"TrialsUnited.com. Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease. ClinicalTrials.gov Identifier: NCT00366145 2013."},{"key":"e_1_3_3_11_2","unstructured":"US National Institutes of Health. Efficacy and safety of adult human mesenchymal stem cells to treat steroid refractory acute graft versus host disease. ClinicalTrials.gov Identifier: NCT00366145 2011."},{"key":"e_1_3_3_12_2","unstructured":"Mesoblast Ltd. News Release Reported via Globe Newswire. Mesoblast acquires Osiris' culture expanded stem cell therapeutic business. 10 October 2013."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.873027"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2012.10.002"},{"key":"e_1_3_3_15_2","unstructured":"HOVON Studies SCT. Stem cell transplantation and cellular therapies. HOVON 112 MSC 2013."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700786"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12154"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tea.2013.0160"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-008-0724-3"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2010.02.026"},{"key":"e_1_3_3_21_2","unstructured":"US National Institutes of Health. Dendritic cell vaccination for patients with solid tumors. ClinicalTrials.gov Identifier: NCT01291420 2013."},{"key":"e_1_3_3_22_2","unstructured":"US National Institutes of Health. Phase II study with hiltonol and dendritic cells in solid tumors. ClinicalTrials.gov Identifier: NCT01734564 2013."},{"key":"e_1_3_3_23_2","unstructured":"US National Institutes of Health. ADIPOA\u2013clinical study. ClinicalTrials.gov Identifier: NCT01585857 2014."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2741"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2013.01.002"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0363546509335463"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.159"},{"key":"e_1_3_3_28_2","unstructured":"US National Institutes of Health. Reparation of cartilage injuries in the human knee by implantation of fresh human allogeneic chondrocytes. ClinicalTrials.gov Identifier: NCT00263432 2013."},{"key":"e_1_3_3_29_2","unstructured":"European Medicines Agency. Guideline on human cell-based medicinal products EMEA\/CHMP\/410869\/2006. www.ema.europa.eu\/pdfs\/human\/cpwp\/41086906enfin.pdf 2008."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3052"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008558"}],"container-title":["Tissue Engineering Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/ten.tea.2014.0515","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ten.tea.2014.0515","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ten.tea.2014.0515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:44:23Z","timestamp":1777697063000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/ten.tea.2014.0515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,23]]},"references-count":30,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1089\/ten.tea.2014.0515"],"URL":"https:\/\/doi.org\/10.1089\/ten.tea.2014.0515","relation":{},"ISSN":["1937-3341","1937-335X"],"issn-type":[{"value":"1937-3341","type":"print"},{"value":"1937-335X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,23]]}}}